Why the study?
Preprocedural imaging may improve identification of arrhythmogenic substrates during VT ablation, particularly in patients with nonischemic cardiomyopathy who have suboptimal outcomes.
Does preprocedural imaging-guided ventricular tachycardia ablation result in similar safety and long-term efficacy in patients with nonischemic cardiomyopathy compared to ischemic cardiomyopathy?
Does preprocedural imaging-guided ventricular tachycardia ablation result in similar safety and long-term efficacy in patients with nonischemic cardiomyopathy compared to ischemic cardiomyopathy?
Preprocedural imaging-guided VT ablation yields comparable long-term efficacy and safety in patients with nonischemic and ischemic cardiomyopathy, with further prognostic benefits when activation mapping is added to substrate ablation.
Answers are grounded in this paper and cite their sources.
Observational data suggest comparable long-term outcomes with imaging-guided VT ablation in NICM and ICM; leaves open randomized confirmation of activation mapping benefit.
Background Integration of preprocedural imaging techniques in ventricular tachycardia (VT) ablation may improve the identification of arrhythmogenic substrates, particularly relevant for patients with nonischemic cardiomyopathy (NICM) with sub‐optimal outcomes. We assessed the impact of advanced preprocedural imaging on the safety and long‐term efficacy of radiofrequency catheter ablation (RCA) for VT, comparing patients with NICM and ischemic cardiomyopathy (ICM). Methods In this prospective, single‐center study, consecutive patients referred for scar‐related VT ablation underwent multidetector computed tomography (MDCT) and late gadolinium enhancement cardiac magnetic resonance (LGE‐CMR). Images were segmented with ADAS 3D software and integrated into mapping systems. Substrate map collection targeted the imaging‐predicted area of interest and the ablation aimed at eliminating all local abnormal ventricular activities. Procedural safety was evaluated with 30‐day mortality. Long‐term efficacy was assessed by survival free from appropriate ICD shocks at 36 months. Results 102 patients were included (67 ± 11 years, 94% male; 75 ICM, 27 NICM). All patients underwent MDCT and 35% also underwent LGE‐CMR. Procedural safety (4% 30‐day mortality, p = .95) and 36‐month efficacy were similar in both groups (88.0% vs. 74.1%, HR 2.09; p = .13 in ICM and NICM). Efficacy was higher in patients when VT activation mapping with VT isthmus ablation complemented substrate ablation compared to substrate‐based ablation alone (94.5% vs. 80.6%, HR 4.00; p < .05). Conclusion A preprocedural imaging protocol integrated into the invasive mapping system may improve safety and long‐term efficacy, with NICM patients exhibiting outcomes comparable to those with ICM. Activation mapping of the VT on top of substrate ablation may improve prognosis.
No takes yet. Share an insight, caveat, or question.
Nunes-Ferreira et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: